CAS NO: | 1818428-24-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | EHP-101 (VCE-004.8) is an orally active, specificPPARγandCB2receptor dual agonist. EHP-101 inhibitsprolyl-hydroxylases (PHDs)and activates theHIFpathway. EHP-101, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. EHP-101 attenuates adipogenesis and prevents diet-induced obesity[1][2]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体内研究 (In Vivo) | EHP-101 (VCE-004.8; i.p.; 20 mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. VCE-004.8 can also significantly ameliorate glucose tolerance, reduce leptin levels (a marker of adiposity) and increase adiponectin and incretins (GLP-1 and GIP) levels[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 433.58 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C28H35NO3 | ||||||||||||||||
CAS 号 | 1818428-24-8 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(115.32 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|